Creative Planning Has $37.42 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Creative Planning raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,467 shares of the pharmaceutical company’s stock after purchasing an additional 1,350 shares during the quarter. Creative Planning’s holdings in Vertex Pharmaceuticals were worth $37,424,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Annapolis Financial Services LLC bought a new position in Vertex Pharmaceuticals during the 1st quarter valued at $27,000. GHP Investment Advisors Inc. purchased a new position in Vertex Pharmaceuticals during the second quarter worth about $29,000. Stephens Consulting LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter worth about $31,000. Founders Capital Management increased its stake in Vertex Pharmaceuticals by 50.0% in the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 25 shares during the last quarter. Finally, ZRC Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $39,000. Institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $488.46, for a total value of $1,113,688.80. Following the completion of the sale, the chief marketing officer now owns 25,539 shares in the company, valued at approximately $12,474,779.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the transaction, the chairman now directly owns 9,994 shares in the company, valued at approximately $4,987,006. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $488.46, for a total transaction of $1,113,688.80. Following the sale, the chief marketing officer now owns 25,539 shares of the company’s stock, valued at approximately $12,474,779.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,285 shares of company stock worth $7,101,755 in the last ninety days. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Down 3.2 %

VRTX stock opened at $483.00 on Monday. The company’s 50 day moving average is $475.21 and its 200 day moving average is $460.23. The stock has a market cap of $124.66 billion, a price-to-earnings ratio of -237.93 and a beta of 0.40. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. Vertex Pharmaceuticals’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm earned $3.53 EPS. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of research analyst reports. HC Wainwright increased their price target on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada dropped their target price on shares of Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Bank of America reduced their price objective on Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating for the company in a report on Monday, October 14th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $492.92.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.